Ventripoint Appoints Dr. Gregory Skinner to Board of Clinical Advisors
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce that Dr. Gregory Skinner has joined its Board of Clinical Advisors.
Dr. Skinner is currently a Consultant Paediatric Cardiologist at the East Midlands Congenital Heart Centre in Leicester, UK and is the Clinical Lead for the Department of Paediatric Cardiology and Deputy Head of Service for the East Midlands Congenital Heart Centre. On top of paediatric cardiology, Dr. Skinner is well versed in advanced imaging, particularly transthoracic and transoesophageal echocardiography in congenital heart disease. He also specializes in paediatric and congenital cardiac x-ray computed tomography (CT) and magnetic resonance imaging (MRI).
Dr. Skinner is certified in Congenital Heart Disease Echocardiography from the European Society of Cardiovascular imaging and a member of the Royal College of Paediatrics and Child Health (MRCPCH).
“I have been using the Ventripoint system since 2014, and it has proved to be a valuable tool for measuring right ventricular size and function in patients with congenital heart disease. It is an excellent adjunct to MRI, allowing accurate and reproducible measurements by using echocardiography. This is particularly helpful for patients who cannot tolerate MRI without sedation or anaesthesia (for example, young children and patients with developmental delay or intellectual disability) and for those for whom MRI is contraindicated (for example, patient with non-MRI compatible pacing systems). Additionally, as the scans are quicker and can be done in an outpatient setting, we can perform more regular right ventricular assessments than we could by using MRI alone. We find that monitoring the trends in the measurements over time gives us valuable insight into the conditions we treat, which improves our decision-making process.
I am very excited to join the Ventripoint team as a clinical advisor, as I believe that we have just seen the tip of the iceberg of what this technology can offer in terms of detailed assessment of the right heart, and the insights that this can give us in caring for our patients.” stated Dr. Skinner.
As an early adopter of the VMS+, Dr. Skinner’s input and clinical experience has been invaluable to Ventripoint over the years. In this new position, Dr. Skinner’s insights will be further utilized in applications and product development.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Dr. George Adams
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.